These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 8500242

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. The V-HeFT VA Cooperative Studies Group.
    Cintron G, Johnson G, Francis G, Cobb F, Cohn JN.
    Circulation; 1993 Jun; 87(6 Suppl):VI17-23. PubMed ID: 8500235
    [Abstract] [Full Text] [Related]

  • 3. Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. The V-HeFT VA Cooperative Studies Group.
    Loeb HS, Johnson G, Henrick A, Smith R, Wilson J, Cremo R, Cohn JN.
    Circulation; 1993 Jun; 87(6 Suppl):VI78-87. PubMed ID: 8500244
    [Abstract] [Full Text] [Related]

  • 4. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group.
    Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A.
    Circulation; 1993 Jun; 87(6 Suppl):VI40-8. PubMed ID: 8500238
    [Abstract] [Full Text] [Related]

  • 5. Hydralazine and isosorbide dinitrate combination improves exercise tolerance in heart failure. Results from V-HeFT I and V-HeFT II. The V-HeFT VA Cooperative Studies Group.
    Ziesche S, Cobb FR, Cohn JN, Johnson G, Tristani F.
    Circulation; 1993 Jun; 87(6 Suppl):VI56-64. PubMed ID: 8500241
    [Abstract] [Full Text] [Related]

  • 6. Influence of prerandomization (baseline) variables on mortality and on the reduction of mortality by enalapril. Veterans Affairs Cooperative Study on Vasodilator Therapy of Heart Failure (V-HeFT II). V-HeFT VA Cooperative Studies Group.
    Johnson G, Carson P, Francis GS, Cohn JN.
    Circulation; 1993 Jun; 87(6 Suppl):VI32-9. PubMed ID: 8500237
    [Abstract] [Full Text] [Related]

  • 7. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. The V-HeFT VA Cooperative Studies Group.
    Cohn JN, Johnson GR, Shabetai R, Loeb H, Tristani F, Rector T, Smith R, Fletcher R.
    Circulation; 1993 Jun; 87(6 Suppl):VI5-16. PubMed ID: 8500240
    [Abstract] [Full Text] [Related]

  • 8. The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. The V-HeFT VA Cooperative Studies Group.
    Carson PE, Johnson GR, Dunkman WB, Fletcher RD, Farrell L, Cohn JN.
    Circulation; 1993 Jun; 87(6 Suppl):VI102-10. PubMed ID: 8500233
    [Abstract] [Full Text] [Related]

  • 9. Mild systolic dysfunction in heart failure (left ventricular ejection fraction >35%): baseline characteristics, prognosis and response to therapy in the Vasodilator in Heart Failure Trials (V-HeFT).
    Carson P, Johnson G, Fletcher R, Cohn J.
    J Am Coll Cardiol; 1996 Mar 01; 27(3):642-9. PubMed ID: 8606276
    [Abstract] [Full Text] [Related]

  • 10. Mechanism of death in heart failure. The Vasodilator-Heart Failure Trials. The V-HeFT VA Cooperative Studies Group.
    Goldman S, Johnson G, Cohn JN, Cintron G, Smith R, Francis G.
    Circulation; 1993 Jun 01; 87(6 Suppl):VI24-31. PubMed ID: 8500236
    [Abstract] [Full Text] [Related]

  • 11. Vasodilators in heart failure. Conclusions from V-HeFT II and rationale for V-HeFT III.
    Cohn JN.
    Drugs; 1994 Jun 01; 47 Suppl 4():47-57; discussion 57-8. PubMed ID: 7523062
    [Abstract] [Full Text] [Related]

  • 12. Incidence of thromboembolic events in congestive heart failure. The V-HeFT VA Cooperative Studies Group.
    Dunkman WB, Johnson GR, Carson PE, Bhat G, Farrell L, Cohn JN.
    Circulation; 1993 Jun 01; 87(6 Suppl):VI94-101. PubMed ID: 8500246
    [Abstract] [Full Text] [Related]

  • 13. Influence of age on mechanisms and prognosis of heart failure. The V-HeFT VA Cooperative Studies Group.
    Hughes CV, Wong M, Johnson G, Cohn JN.
    Circulation; 1993 Jun 01; 87(6 Suppl):VI111-7. PubMed ID: 8500234
    [Abstract] [Full Text] [Related]

  • 14. Enalapril decreases prevalence of ventricular tachycardia in patients with chronic congestive heart failure. The V-HeFT II VA Cooperative Studies Group.
    Fletcher RD, Cintron GB, Johnson G, Orndorff J, Carson P, Cohn JN.
    Circulation; 1993 Jun 01; 87(6 Suppl):VI49-55. PubMed ID: 8500239
    [Abstract] [Full Text] [Related]

  • 15. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study.
    Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH.
    N Engl J Med; 1986 Jun 12; 314(24):1547-52. PubMed ID: 3520315
    [Abstract] [Full Text] [Related]

  • 16. Evaluation by patients with heart failure of the effects of enalapril compared with hydralazine plus isosorbide dinitrate on quality of life. V-HeFT II. The V-HeFT VA Cooperative Studies Group.
    Rector TS, Johnson G, Dunkman WB, Daniels G, Farrell L, Henrick A, Smith B, Cohn JN.
    Circulation; 1993 Jun 12; 87(6 Suppl):VI71-7. PubMed ID: 8500243
    [Abstract] [Full Text] [Related]

  • 17. The Vasodilator-Heart Failure Trials (V-HeFT). Mechanistic data from the VA Cooperative Studies. Introduction.
    Cohn JN.
    Circulation; 1993 Jun 12; 87(6 Suppl):VI1-4. PubMed ID: 8500232
    [No Abstract] [Full Text] [Related]

  • 18. Lessons from V-HeFT: questions for V-HeFT II and the future therapy of heart failure.
    Cohn JN.
    Herz; 1991 Sep 12; 16 Spec No 1():267-71. PubMed ID: 1820292
    [Abstract] [Full Text] [Related]

  • 19. Effect of vasodilator therapy on mortality in chronic congestive heart failure.
    Cohn JN.
    Eur Heart J; 1988 Jan 12; 9 Suppl A():171-3. PubMed ID: 3044793
    [Abstract] [Full Text] [Related]

  • 20. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group.
    Carson P, Ziesche S, Johnson G, Cohn JN.
    J Card Fail; 1999 Sep 12; 5(3):178-87. PubMed ID: 10496190
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.